Skip to main content
Journal cover image

Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

Publication ,  Journal Article
Shah, NP; Pajidipati, NJ; McGarrah, RW; Navar, AM; Vemulapalli, S; Blazing, MA; Shah, SH; Hernandez, AF; Patel, MR
Published in: The American journal of cardiology
July 2020

Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The American journal of cardiology

DOI

EISSN

1879-1913

ISSN

0002-9149

Publication Date

July 2020

Volume

126

Start / End Page

94 / 102

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Risk Assessment
  • Primary Prevention
  • Peripheral Arterial Disease
  • Oligonucleotides, Antisense
  • Lipoprotein(a)
  • Humans
  • Genetic Predisposition to Disease
  • Diabetes Mellitus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, N. P., Pajidipati, N. J., McGarrah, R. W., Navar, A. M., Vemulapalli, S., Blazing, M. A., … Patel, M. R. (2020). Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. The American Journal of Cardiology, 126, 94–102. https://doi.org/10.1016/j.amjcard.2020.03.043
Shah, Nishant P., Neha J. Pajidipati, Robert W. McGarrah, Ann Marie Navar, Sreekanth Vemulapalli, Michael A. Blazing, Svati H. Shah, Adrian F. Hernandez, and Manesh R. Patel. “Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.The American Journal of Cardiology 126 (July 2020): 94–102. https://doi.org/10.1016/j.amjcard.2020.03.043.
Shah NP, Pajidipati NJ, McGarrah RW, Navar AM, Vemulapalli S, Blazing MA, et al. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. The American journal of cardiology. 2020 Jul;126:94–102.
Shah, Nishant P., et al. “Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.The American Journal of Cardiology, vol. 126, July 2020, pp. 94–102. Epmc, doi:10.1016/j.amjcard.2020.03.043.
Shah NP, Pajidipati NJ, McGarrah RW, Navar AM, Vemulapalli S, Blazing MA, Shah SH, Hernandez AF, Patel MR. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. The American journal of cardiology. 2020 Jul;126:94–102.
Journal cover image

Published In

The American journal of cardiology

DOI

EISSN

1879-1913

ISSN

0002-9149

Publication Date

July 2020

Volume

126

Start / End Page

94 / 102

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Risk Assessment
  • Primary Prevention
  • Peripheral Arterial Disease
  • Oligonucleotides, Antisense
  • Lipoprotein(a)
  • Humans
  • Genetic Predisposition to Disease
  • Diabetes Mellitus